Sermorelin and estrogen: hormone therapy and IGF-1 interpretation

What the estrogen studies measured

The 1991 study compared oral ethinyl estradiol with transdermal estradiol in small groups over two months. Oral treatment raised GH while reducing circulating IGF-1; the transdermal regimen had a different pattern. Both the route and the preparations need to be kept in mind when interpreting those findings.

A 1993 crossover study examined three oral estrogen formulations in six postmenopausal women. It also found reduced IGF-1 alongside increased GH. These small physiological studies explain why a medication list can matter to a laboratory interpretation; they do not establish an ideal sermorelin regimen for women using estrogen.

One result may reflect more than one influence

Tell the clinician about recent changes in estrogen formulation, route, or instructions. Include whether other hormone therapy is used. A laboratory change that follows several treatment changes cannot automatically be assigned to sermorelin alone.

Our IGF-1 guide explains why results need clinical context. Ask whether the current therapy changes the interpretation and whether testing should be coordinated with the clinician who manages hormone treatment. A higher number is not a universal goal independent of symptoms and diagnosis.

Menopause treatment addresses a different question

ACOG describes menopause hormone therapy as treatment for relevant menopausal symptoms. The benefits, risks, and appropriate preparation depend on the individual. Evidence supporting that use does not establish that a GH-related peptide should replace it or be routinely added.

If the main concern is hot flashes, vaginal symptoms, or another menopause-related problem, identify that concern directly at the appointment. Our guide for women discusses how to separate symptom goals from broad anti-aging marketing. A treatment should be evaluated against the problem it is actually meant to address.

Do not switch routes to improve a peptide number

The research does not justify independently changing oral estrogen to a patch or altering the dose to make an IGF-1 result look different. Route selection involves a wider medical assessment than its effect on one hormone marker. Discuss any proposed change with the clinician responsible for that prescription.

Similarly, do not add sermorelin just to counter a laboratory effect attributed to estrogen. Ask whether the finding represents a clinical problem, whether it affects diagnosis, and what evidence supports the proposed response. These questions should be answered before a new medication becomes the default solution.

Coordinate the care plan

If the hormone prescriber and peptide service are separate, ask who will reconcile the medication list and review results. Bring the actual product labels rather than reporting only that you take “HRT.” Our interaction guide helps organize this information.

The appointment should end with a clear explanation of what is known, what remains uncertain, and who will follow up. Neither a small estrogen physiology study nor a general claim about GH stimulation can establish that a sermorelin/estrogen combination is necessary or beneficial for every woman experiencing age-related changes.